Ziprasidone: Pharmacology, clinical progress and therapeutic promise

P. F. Buckley

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Choosing among the atypical antipsychotics currently available for the treatment of schizophrenia requires the clinician to evaluate the relative merits of each agent. Ziprasidone is another atypical antipsychotic, currently under consideration for approval to use in clinical practice, whose role is at present under review. Based upon the information reviewed here, ziprasidone is an agent which possesses the preclinical and clinical attributes which characterize an 'atypical' antipsychotic and is an effective antipsychotic medication for the treatment of psychosis. Ziprasidone appears to discriminate from other atypical antipsychotics by its low propensity for weight gain and by the availability of a short-acting intramuscular formulation. Its role in clinical practice will be determined by clinician experience and by additional phase IV clinical trials. (C) 2000 Prous Science.

Original languageEnglish (US)
Pages (from-to)583-589
Number of pages7
JournalDrugs of Today
Volume36
Issue number8
DOIs
StatePublished - Jan 1 2000

Fingerprint

Clinical Pharmacology
Antipsychotic Agents
Phase IV Clinical Trials
Therapeutics
Psychotic Disorders
Weight Gain
Schizophrenia
ziprasidone

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ziprasidone : Pharmacology, clinical progress and therapeutic promise. / Buckley, P. F.

In: Drugs of Today, Vol. 36, No. 8, 01.01.2000, p. 583-589.

Research output: Contribution to journalReview article

Buckley, P. F. / Ziprasidone : Pharmacology, clinical progress and therapeutic promise. In: Drugs of Today. 2000 ; Vol. 36, No. 8. pp. 583-589.
@article{ce2195d434f4429c98d060b228ed92b4,
title = "Ziprasidone: Pharmacology, clinical progress and therapeutic promise",
abstract = "Choosing among the atypical antipsychotics currently available for the treatment of schizophrenia requires the clinician to evaluate the relative merits of each agent. Ziprasidone is another atypical antipsychotic, currently under consideration for approval to use in clinical practice, whose role is at present under review. Based upon the information reviewed here, ziprasidone is an agent which possesses the preclinical and clinical attributes which characterize an 'atypical' antipsychotic and is an effective antipsychotic medication for the treatment of psychosis. Ziprasidone appears to discriminate from other atypical antipsychotics by its low propensity for weight gain and by the availability of a short-acting intramuscular formulation. Its role in clinical practice will be determined by clinician experience and by additional phase IV clinical trials. (C) 2000 Prous Science.",
author = "Buckley, {P. F.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1358/dot.2000.36.8.591837",
language = "English (US)",
volume = "36",
pages = "583--589",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "8",

}

TY - JOUR

T1 - Ziprasidone

T2 - Pharmacology, clinical progress and therapeutic promise

AU - Buckley, P. F.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Choosing among the atypical antipsychotics currently available for the treatment of schizophrenia requires the clinician to evaluate the relative merits of each agent. Ziprasidone is another atypical antipsychotic, currently under consideration for approval to use in clinical practice, whose role is at present under review. Based upon the information reviewed here, ziprasidone is an agent which possesses the preclinical and clinical attributes which characterize an 'atypical' antipsychotic and is an effective antipsychotic medication for the treatment of psychosis. Ziprasidone appears to discriminate from other atypical antipsychotics by its low propensity for weight gain and by the availability of a short-acting intramuscular formulation. Its role in clinical practice will be determined by clinician experience and by additional phase IV clinical trials. (C) 2000 Prous Science.

AB - Choosing among the atypical antipsychotics currently available for the treatment of schizophrenia requires the clinician to evaluate the relative merits of each agent. Ziprasidone is another atypical antipsychotic, currently under consideration for approval to use in clinical practice, whose role is at present under review. Based upon the information reviewed here, ziprasidone is an agent which possesses the preclinical and clinical attributes which characterize an 'atypical' antipsychotic and is an effective antipsychotic medication for the treatment of psychosis. Ziprasidone appears to discriminate from other atypical antipsychotics by its low propensity for weight gain and by the availability of a short-acting intramuscular formulation. Its role in clinical practice will be determined by clinician experience and by additional phase IV clinical trials. (C) 2000 Prous Science.

UR - http://www.scopus.com/inward/record.url?scp=0033776312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033776312&partnerID=8YFLogxK

U2 - 10.1358/dot.2000.36.8.591837

DO - 10.1358/dot.2000.36.8.591837

M3 - Review article

C2 - 12847582

AN - SCOPUS:0033776312

VL - 36

SP - 583

EP - 589

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 8

ER -